Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure

Journal of Cardiac Failure

Volumn 13, Issue 5, 2007, Pages 365-371

  Nagatomo, Yuji ^a   Yoshikawa, Tsutomu ^a   Kohno, Takashi ^a   Yoshizawa, Akihiro ^a   Anzai, Toshihisa ^a   Meguro, Tomomi ^b   Satoh, Toru ^a   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO ELECTRIC POWER COMPANY   (Japan)

Author keywords

cardiac function; inflammation; Interleukin 6; oxidative stress

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 6; LIPID PEROXIDE; METOPROLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; VALVULAR HEART DISEASE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARBAZOLES; EXERCISE TOLERANCE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; LIPID PEROXIDATION; MALE; METOPROLOL; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PROPANOLAMINES; RADIONUCLIDE VENTRICULOGRAPHY; SINGLE-BLIND METHOD;

EID: 34250804754     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.02.004     Document Type: Article

References (34)

1. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
2. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
3. Yin W.H., Chen J.W., Jen H.L., Chiang M.C., Huang W.P., Feng A.N., et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147 (2004) 931-938
4. Anand I.S., Latini R., Florea V.G., Kuskowski M.A., Rector T., Masson S., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
5. Murray D.R., Prabhu S.D., and Chandrasekar B. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101 (2000) 2338-2341
6. Prabhu S.D., Chandrasekar B., Murray D.R., and Freeman G.L. β-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101 (2000) 2103-2109
7. Gullestad L., Ueland T., Brunsvig A., Kjekshus J., Simonsen S., Froland S.S., et al. Effect of metoprolol on cytokine levels in chronic heart failure-A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 141 (2001) 418-421
8. Ohtsuka T., Hamada M., Hiasa G., Sasaki O., Suzuki M., Hara Y., et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37 (2001) 412-417
9. Ohtsuka T., Hamada M., Saeki H., Ogimoto A., Hiasa G., Hara Y., et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89 (2002) 996-999
10. Mayer B., Holmer S.R., Hengstenberg C., Lieb W., Pfeifer M., and Schunkert H. Functional improvement in heart failure patients treated with beta blockers is associated with a decline of cytokine levels. Int J Cardiol 103 (2005) 182-186
11. Kohno T., Yoshikawa T., Yoshizawa A., Nakamura I., Anzai T., Satoh T., et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther 19 (2005) 347-355
12. Ledue T.B., Weiner D.L., Sipe J., Poulin S.E., Collins M.F., and Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem 35 (1998) 745-753
13. Tateishi T., Yoshimine N., and Kuzuya F. Serum lipid peroxide assayed by a new colorimetric method. Exp Gerontol 22 (1987) 103-111
14. Pye M., Rae A.P., and Cobbe S.M. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 63 (1990) 228-230
15. Sato Y., Takatsu Y., Kataoka K., Yamada T., Taniguchi R., Sasayama S., et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute heart decompensation. Clin Cardiol 22 (1999) 811-813
16. Kaneko K., Kanda T., Yamauchi Y., Hasegawa A., Iwasaki T., Arai M., et al. C-reactive protein in dilated cardiomyopathy. Cardiology 91 (1999) 215-219
17. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 35 (2000) 1628-1637
18. Lamblin N., Mouquet F., Hennache B., Dagom J., Susen S., Bauters C., et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 26 (2005) 2245-2250
19. Takahashi T., Anzai T., Yoshikawa T., Maekawa Y., Asakura Y., Satoh T., et al. Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction-role of neurohormones and cytokines. Int J Cardiol 88 (2003) 257-265
20. Anzai T., Yoshikawa T., Takahashi T., Maekawa Y., Okabe T., Asakura Y., et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 99 (2003) 47-53
21. Joynt K.E., Gattis W.A., Hasselblad V., Fuzaylov S.Y., Serebruany V.L., Gurbel P.A., et al. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 93 (2004) 783-785
22. Gilbert E.M., Abraham W.T., Olsen S., Hattler B., White M., Mealy P., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
23. Kukin M.L., Kalman J., Charney R.H., Levy D.K., Buchholz-Varley C., Ocampo O.N., et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99 (1999) 2645-2651
24. Josephson R.A., Silverman H.S., Lakatta E.G., Stern M.D., and Zweier J.L. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem 266 (1991) 2354-2361
25. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85 (1999) 357-363
26. Dalton T.P., Shertzer H.G., and Puga A. Regulation of gene expression by reactive oxygen. Ann Rev Pharmacol Toxicol 39 (1999) 67-101
27. Tsutamoto T., Wada A., Matsumoto T., Maeda K., Mabuchi N., Hayashi M., et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts patients with dilated cardiomyopathy. J Am Coll Cardiol 37 (2001) 2086-2092
28. Nakamura K., Kusano K., Nakamura Y., Kakishita M., Ohta K., Nagase S., et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105 (2002) 2867-2871
29. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., et al. Carvedilol, a new vasodilator and β-adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263 (1992) 92-98
30. Dandona P., Karne R., Ghanim H., Hamouda W., Alijada A., and Magsino Jr. C.H. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101 (2000) 122-124
31. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
32. Poole-Wilson P.A., Swedberg K., Cleland J.G., DiLenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
33. Venugopal S.K., Devaraj S., and Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166 (2005) 1265-1271
34. Kang D.H., Park S.K., Lee I.K., and Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16 (2005) 3553-3562